Cilastatin

Name: Cilastatin
Brand: Selleck Chemicals
SKU: S5621
Rating: 5 (1 reviews)

Synonyms: MK0791

Catalog No.S5621 Purity:99.95%

Cilastatin(MK0791) is a renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor.

Cilastatin Chemical Structure

CAS No. 82009-34-5

Purity & Quality Control

Batch: Purity: 99.95%

99.95

Cilastatin Related Products

Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole NAD+ 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Pitstop 2 Sesamin Bilobalide Formononetin Hesperidin Palmitic acid Azeliragon (TTP488) L-Mimosine Ademetionine Carbenoxolone Sodium GO-203 Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate Ethylenediaminetetraacetic acid Silibinin (NSC 651520) (+)-Fangchinoline Bergenin Spermine NB 598 DMNQ (20S)Ginsenoside Rg2 Farrerol EGCG Octaacetate D-(+)-Trehalose dihydrate Reboxetine mesylate E7820 Hydroxytyrosol Evofosfamide (TH-302) Bromhexine HCl 5-hydroxytryptophan (5-HTP) Inosine D-Mannose Anethole trithione Sodium Nitroprusside Dihydrate Alendronic Acid 2,4-Pyridinedicarboxylic acid GSK805 ADP Acipimox Curcumin analog C1 Trimetazidine 2,2,2-Tribromoethanol Sulfopin N-Acetylneuraminic acid Quinacrine Dihydrochloride Dihydrate L-methionine Stigmasterol Oleanonic Acid Substance P TFA Achyranthes bidentata root Extract Ginsenoside Rg3 Phyllanthus Urinaria Extract NSI-189 SR8278 Lycopene Trometamol hydrochloride 1-Methyl-3-nitro-1-nitrosoguanidine (MNNG) Ureidosuccinic acid Tea polyphenol Fructose (+)-JQ1 carboxylic acid Ligustilide Polybrene (Hexadimethrine Bromide) Pinoresinol diglucoside 4-HNE (4-Hydroxynonenal) Iron Dextran Sodium Picosulfate IM-54 Disufenton sodium Troxipide Orcinol glucoside Diludine 20R-Camptothecin (+)-Usniacin 3-Indolebutyric acid (IBA) HEPES Cremophor EL BMS-986176 DTT (Dithiothreitol) Esculin Methyl Eugenol Polyinosinic acid-polycytidylic acid L-(-)-Glucose 1-Hydroxy-2-naphthoic acid Azomycin 3-Hydroxybenzoic acid Emlenoflast (MCC-7840) β-Alanine β-Sitosterol Rat IgG1 isotype control-InVivo Aminomalonic acid Helecin BRM/BRG1 ATP Inhibitor-1 23-Hydroxybetulinic acid PZ-2891 Toosendanin 1,2-Propanediol Epibrassinolide Cyanidin-3-O-glucoside chloride Dihydrotanshinone I Gracillin Sodium Pyruvate Itaconic acid FH1 Cinnamic acid Guanidine HCl Triethylenetetramine 2HCl Molsidomine Calcium D-saccharate tetrahydrate Creatine monohydrate DL-Dopa FPH1 5'-Adenylic acid Acetamide ML329 Pterostilbene Kinetin Acetyl Resveratrol GSK4112 LTI-291 Plantamajoside Anhydroicaritin BZ1 Phloretic acid Anemoside B4 EGTA Sucralose 6-Chloropurine Glucosamine hydrochloride Sinoacutine 2,4-Dihydroxyacetophenone Stearic acid Stevioside Morin PMPA tetrasodium salt L-Hydroorotic acid Irigenin Behenic Acid CTX-0294885 Fudosteine (R)-(-)-JQ1 Enantiomer 2'-Deoxyguanosine monohydrate L-Tryptophanamide Hydrochloride β-Cyclodextrin 3-Indolepropionic acid DL-Citrulline Sclareol Methyl protocatechuate Sodium nitroprusside N-Nitrosodiethylamine Deoxyaconitine N-Acetyl-L-methionine Sinapine thiocyanate Sodium succinate Senkyunolide A L-Tryptophan Swertiamarin Octyl gallate Brassinazole	Click to Expand
Related Compound Libraries	Metabolism Compound Library Anti-cancer Metabolism Compound Library Glutamine Metabolism Compound Library Carbohydrate Metabolism Compound Library Lipid Metabolism Compound Library	Click to Expand

Biological Activity

Description

Cilastatin(MK0791) is a renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor.

Targets

dehydropeptidase-I ^[1]

leukotriene D4 dipeptidase ^[2]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04802863	Completed	Bacterial Infections	Evopoint Biosciences Inc.	March 25 2021	Phase 1
NCT04801043	Completed	Bacterial Infections	Evopoint Biosciences Inc.	March 2 2021	Phase 1
NCT04787562	Completed	Bacterial Infections	Evopoint Biosciences Inc.	February 25 2021	Phase 1
NCT03595189	Completed	Dose Finding Study	Spherium Biomed\|Hospital Universitario La Paz	June 19 2018	Phase 1
NCT03230916	Completed	Suspected or Documented Gram-negative Bacterial Infection	Merck Sharp & Dohme LLC	November 6 2017	Phase 1

References

Chemical Information & Solubility

Molecular Weight	358.45	Formula	C₁₆H₂₆N₂O₅S
CAS No.	82009-34-5	SDF	--
Smiles	CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)O)C
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 72 mg/mL ( (200.86 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 7 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):